Switchkine raises CHF 250,000

Switchkine develops pH-activatable cytokines to treat cancer and autoimmune and inflammatory diseases. Selected for the Biopôle Investment Programme's Pre-Clinical Top-Up (CHF 250,000), it will fund proof-of-concept studies.

Announced on
Round
Grant
Amount
CHF 250,000
Location
Epalinges, canton of Vaud
Sector
Biotech & life sciences

Investors

Preparing a similar round?

The diagnostic shows you the instruments and investors that fit your stage.

Start the diagnostic